What Is Metocin? Reported Effects, Use Cases & More

Disclaimer: This article is for informational purposes only. It does not constitute medical or legal advice and does not encourage, endorse, or provide guidance on obtaining or consuming metocin or any other unregulated substance. All information is drawn from publicly available peer-reviewed research and is presented strictly to document what the scientific literature currently shows. Nothing in this article should be interpreted as dosing guidance, safety assessment, or encouragement of use. Consult a qualified legal and medical professional before making any decisions based on information contained here.

Psychedelic research has expanded rapidly in recent years, bringing substances like psilocybin mushrooms back into mainstream scientific discussion. As interest in these compounds grows, so does curiosity about lesser-known psychedelics that exist on the edges of the research landscape.

One of those compounds is metocin.

What is metocin? In short, it’s a synthetic psychedelic compound that exists in a largely undocumented space, with limited peer-reviewed research and significant legal uncertainty depending on jurisdiction. 

Reliable information is scarce, which is exactly why understanding what the available science actually says matters. This article documents what current research shows about metocin—its origin, reported effects, and legal status.

• Metocin (chemical name: 4-HO-MET) is a synthetic psychedelic compound first synthesized by Alexander Shulgin, closely related in structure to psilocin, the active compound in psychedelic mushrooms
• Metocin has no approved medical use, no established safety profile, and no completed human clinical trials—it is an unregulated research chemical with unknown long-term effects
• A small Swedish study found that participants described 4-HO-MET experiences as shifting between “heaven” and “hell,” with drastic changes in cognitive, emotional, and bodily function
• Reported effects appear similar to psilocybin and psilocin, based on both Shulgin’s own accounts and the limited available literature
• Metocin is not federally scheduled in the United States, but may be treated as a Schedule I controlled substance under the Federal Analogue Act due to its structural similarity to psilocin
• Some states (including South Dakota and West Virginia) have explicitly scheduled it; internationally, legal status varies significantly by country.

Metocin, formally known as 4-hydroxy-N-methyl-N-ethyltryptamine, or 4-HO-MET, is a synthetic psychedelic compound belonging to the tryptamine class of substances. It is a structural analogue of psilocin (4-HO-DMT), the compound responsible for the psychedelic effects of psilocybin mushrooms. 

Unlike psilocybin, which occurs naturally in certain mushroom species, metocin is entirely lab-synthesized and has no known natural source. It acts as a serotonin receptor agonist, with activity at the 5-HT2A receptor thought to be responsible for its hallucinogenic properties.

Shulgin first synthesized 4-HO-MET in the 1970s, though the compound was first formally described in the scientific literature by David Repke and colleagues in 1981. Shulgin later published his own findings and qualitative observations in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), and the compound emerged as a recreational and designer drug in Europe around 2008. Its 4-HO-MET street name is less commonly used than metocin or methylcybin, the latter of which you’ll occasionally find in online research communities.

But how did this emergence occur? Plain and simple, people were curious about psychedelic experiences and began to experiment. Substances that share structural or pharmacological features with known psychedelics tend to attract interest from people curious about altered states.

Based on available research, 4-HO-MET effects appear broadly similar to those of psilocybin and psilocin. Shulgin himself noted in TiHKAL that he doubted it could be distinguished from psilocin in any blinded clinical study, though he also described it as having a somewhat different character—more clear-headed and functional, while still producing strong visual effects.

The most directly relevant peer-reviewed study is a 2012 Swedish paper published in the Journal of Psychoactive Drugs examining the recreational use of 4-HO-MET. 25 anonymous individuals in Sweden reported their experiences with the compound. Key findings from that study:

• Experiences were described by participants as shifting between “heaven” and “hell”
• Drastic changes in cognitive, emotional, and bodily functions were reported
• The primary motivation for use was described as a strong curiosity
• Participants appeared generally satisfied with the experience
• Reported effects showed similarities to classic psychedelic substances, including LSD and psilocybin

The general reported effects of metocin, drawn from Shulgin’s accounts and the available literature, include:

• Visual hallucinations (altered perception of colors, patterns, and shapes)
• Changes in thought patterns and cognitive function
• Altered emotional states, including both euphoric and dysphoric experiences
• Changes in perception of time
• Bodily sensations including changes in physical awareness
• Potential for anxiety or paranoia, particularly at higher doses
• A reportedly “clear-headed” or “functional” quality that some users and researchers distinguish from psilocin

Psilocin is the compound that produces the psychedelic experience associated with psilocybin mushrooms—psilocybin itself is a prodrug that the body converts to psilocin. Psilocin’s effects typically include visual and auditory hallucinations, shifts in perception of time and self, emotional amplification, and altered thought patterns. Metocin’s structural similarity to psilocin is why its effects are generally compared to mushroom experiences in the available literature.

Important limitation: The effects described above are drawn from a very small evidence base. The Swedish study involved 25 anonymous self-reports, while Shulgin’s accounts are personal qualitative observations. Metocin effects are significantly under-researched, and there is insufficient scientific evidence to pinpoint its effects. Individual responses to psychedelic compounds vary substantially based on dose, set, setting, individual neurochemistry, and other substance use.

Metocin has no approved medical use, no established safety profile, and no completed human clinical trials. These are not minor caveats—they mean that the basic risk parameters associated with metocin consumption are unknown. Long-term effects of exposure are undocumented. Dose-response relationships have not been systematically studied in controlled settings. Interactions with medications, pre-existing health conditions, and other substances have not been characterized.

So, is metocin safe to consume? There is insufficient scientific evidence to assess the safety of metocin consumption. Use carries unknown risks. It’s an unregulated research chemical consumed without pharmaceutical-grade quality control, accurate dosing verification, or safety data for the general population. The metocin side effects that have been informally reported include anxiety, paranoia, nausea, and dysphoric emotional states—consistent with what’s documented for serotonergic psychedelics—but the full side effect profile is unknown. 4-HO-MET side effects at higher doses or in vulnerable populations have not been studied.

Is metocin legal in the United States? The answer is complicated and depends on jurisdiction.

At the federal level, metocin (4-HO-MET) is not specifically scheduled under the Controlled Substances Act. However, the 1986 Federal Analogue Act creates significant legal exposure. Under that law, any substance intended for human consumption that is substantially similar in structure or pharmacological effect to a Schedule I or Schedule II substance is treated as a Schedule I controlled substance.

Given metocin’s close structural relationship to psilocin, which is a Schedule I substance, federal prosecution under the Analogue Act is a real legal risk for possession, distribution, or sale intended for human consumption. Under 21 U.S.C. § 813, the intent-for-human-consumption standard is evaluated using a range of factors, including marketing, labeling, and context of distribution.

At the state level, the metocin legal picture varies. South Dakota and West Virginia have explicitly scheduled 4-HO-MET as a controlled substance. Other states may treat it similarly under analogue provisions in state law.

Internationally, the 4-HO-MET legal status varies significantly. In the United Kingdom, it is classified as a Class A drug under the tryptamine catch-all provision. Germany has implemented controls under the NpSG (New Psychoactive Substances Act). Australia lists it as a Schedule 9 prohibited substance. Sweden and Finland have also implemented specific controls.

The “is metocin legal” question has no universal answer. It depends entirely on jurisdiction, and the legal landscape for research chemicals changes as agencies update their scheduling.

Interest in psychedelics has grown rapidly in recent years, largely driven by new clinical research into psilocybin and other compounds. But outside of tightly controlled research environments, many substances discussed in online communities—including research chemicals like metocin—exist in legal gray areas and lack established safety data.

That uncertainty has contributed to the rise of legal mushroom-inspired and hemp-derived products designed to offer creative or sensory experiences without relying on unregulated research chemicals.

Some companies are exploring this category by blending functional mushrooms, cannabinoids, and other plant compounds to create mood-shifting or perception-enhancing effects within existing regulatory frameworks.

For example, products like Binoid’s Visual Gummies – Moon Melt use proprietary mushroom blends intended to support visual creativity and sensory engagement while operating within the regulated hemp product market.

While these products are not psychedelic substances and should not be compared directly to research chemicals like metocin, their growing popularity reflects a broader cultural trend: increasing curiosity about altered states, creativity, and consciousness—paired with a desire for products that exist within clearer regulatory boundaries.

What is metocin, in summary: a synthetic psychedelic research chemical, structurally related to psilocin, first synthesized by Alexander Shulgin in the 1970s. The limited peer-reviewed research available suggests its effects are broadly similar to those of psilocybin, with reported experiences ranging dramatically from positive to deeply difficult. It has no approved medical use, no established safety profile, and no human clinical trials. Its legal status in the U.S. is a gray area that carries real federal risk under the Analogue Act, and it is explicitly controlled in several states and multiple countries.

The honest picture of 4-HO-MET: it is a poorly studied compound in a regulatory gray zone, with essentially no clinical safety data. Anyone seeking information about this compound should consult legal and medical professionals for jurisdiction-specific guidance. The science on metocin is thin, and more research is needed before anything more definitive can be said.